Oral Medication Approved for MS in Canada

.

Oral Medication Approved for MS in Canada

Multiple Sclerosis treatment is bound to revolutionize in Canada as drug-maker Novartis Pharmaceutical Canada Inc. announced on Thursday that the first oral medicine for the condition has been approved for use by some patients in the country. The medication will basically help in providing treatment for the symptoms of MS.

The medicine has been named Gilenya and will be available for sale from the 1st of April at pharmaceutical stores across the nation. The medicine will be available for people who have tried another treatment for the condition with poor results.

The chemical name for Gilenya is fingolimod and it will be used for people with the relapsing-remitting form of the condition. According to the figures available, the disease ends up affecting an astounding 75,000 Canadians. People with this variety of the condition are likely to experience new symptoms with severity of older symptoms worsening.

Gilenya will help in reducing flare-ups of people suffering from multiple sclerosis and will also help in reducing the rate of progress. Each capsule of Gilenya contains 0.5 milligrams of the drug and is the most convenient treatment for MS in Canada.

Talking about the development, a Neurologist from Toronto, Dr. Daniel Selchan, said: "The approval of Gilenya is a significant milestone for the Canadian MS community".


Latest News

HP Inc. posts better than expected financial results for its fiscal Q3
Tesla announces new Model S and X versions with upgraded battery, super fast acc
Google announces the launch of Android 7.0 ‘Nougat’
Lyft seeking $9B buyout, Uber not willing to pay more than $2B
Recode: Lyft had recently sought $9B in buyout offer
Uber signs $300M deal with Volvo; acquires startup Otto
Instagram introduces new ‘Event Channel’ feature
Ford plans to build a fleet of fully autonomous vehicle by 2021
WSJ: Google is exploring the use of wireless technology for Fiber service
Hacker ‘Guccifer 2.0’ leaks a new set of internal Democratic Party documents
DEA not Reconsidering How Marijuana is Treated under Federal Drug Control Laws
SpaceX Falcon 9 Rocket Launch on Sunday: Rocket to Take JCSAT-16 Communications